RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Michele Carbone to Humans

This is a "connection" page, showing publications Michele Carbone has written about Humans.
Connection Strength

2.142
  1. Carbone M, Minaai M, Takinishi Y, Pagano I, Yang H. Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma. J Transl Med. 2023 10 25; 21(1):749.
    View in: PubMed
    Score: 0.046
  2. Carbone M, Yang H, Pass HI, Taioli E. Did the Ban on Asbestos Reduce the Incidence of Mesothelioma? J Thorac Oncol. 2023 06; 18(6):694-697.
    View in: PubMed
    Score: 0.045
  3. Bononi A, Wang Q, Zolondick AA, Bai F, Steele-Tanji M, Suarez JS, Pastorino S, Sipes A, Signorato V, Ferro A, Novelli F, Kim JH, Minaai M, Takinishi Y, Pellegrini L, Napolitano A, Xu R, Farrar C, Goparaju C, Bassi C, Negrini M, Pagano I, Sakamoto G, Gaudino G, Pass HI, Onuchic JN, Yang H, Carbone M. BAP1 is a novel regulator of HIF-1a. Proc Natl Acad Sci U S A. 2023 01 24; 120(4):e2217840120.
    View in: PubMed
    Score: 0.044
  4. Yang H, Gaudino G, Bardelli F, Carbone M. Does the Amount of Asbestos Exposure Influence Prognosis? J Thorac Oncol. 2022 08; 17(8):949-952.
    View in: PubMed
    Score: 0.042
  5. Carbone M, Pass HI, Ak G, Alexander HR, Baas P, Baumann F, Blakely AM, Bueno R, Bzura A, Cardillo G, Churpek JE, Dianzani I, De Rienzo A, Emi M, Emri S, Felley-Bosco E, Fennell DA, Flores RM, Grosso F, Hayward NK, Hesdorffer M, Hoang CD, Johansson PA, Kindler HL, Kittaneh M, Krausz T, Mansfield A, Metintas M, Minaai M, Mutti L, Nielsen M, O'Byrne K, Opitz I, Pastorino S, Pentimalli F, de Perrot M, Pritchard A, Ripley RT, Robinson B, Rusch V, Taioli E, Takinishi Y, Tanji M, Tsao AS, Tuncer AM, Walpole S, Wolf A, Yang H, Yoshikawa Y, Zolondick A, Schrump DS, Hassan R. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. J Thorac Oncol. 2022 07; 17(7):873-889.
    View in: PubMed
    Score: 0.041
  6. Zhang L, Vunnamadala SP, Yagi S, Meraj R, Carbone M. Delayed positive COVID19 nasopharyngeal test, a case study with clinical and pathological correlation. BMC Pulm Med. 2021 Aug 31; 21(1):278.
    View in: PubMed
    Score: 0.040
  7. Carbone M, Lednicky J, Xiao SY, Venditti M, Bucci E. Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For. J Thorac Oncol. 2021 04; 16(4):546-571.
    View in: PubMed
    Score: 0.038
  8. Bononi A, Goto K, Ak G, Yoshikawa Y, Emi M, Pastorino S, Carparelli L, Ferro A, Nasu M, Kim JH, Suarez JS, Xu R, Tanji M, Takinishi Y, Minaai M, Novelli F, Pagano I, Gaudino G, Pass HI, Groden J, Grzymski JJ, Metintas M, Akarsu M, Morrow B, Hassan R, Yang H, Carbone M. Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma. Proc Natl Acad Sci U S A. 2020 12 29; 117(52):33466-33473.
    View in: PubMed
    Score: 0.038
  9. Carbone M, Harbour JW, Brugarolas J, Bononi A, Pagano I, Dey A, Krausz T, Pass HI, Yang H, Gaudino G. Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer. Cancer Discov. 2020 08; 10(8):1103-1120.
    View in: PubMed
    Score: 0.037
  10. Carbone M. Transitional Mesothelioma and Artificial Intelligence: Do We Need One More Subtype? and Do We Need Computers to Identify Them? J Thorac Oncol. 2020 06; 15(6):884-887.
    View in: PubMed
    Score: 0.036
  11. Carbone M, Arron ST, Beutler B, Bononi A, Cavenee W, Cleaver JE, Croce CM, D'Andrea A, Foulkes WD, Gaudino G, Groden JL, Henske EP, Hickson ID, Hwang PM, Kolodner RD, Mak TW, Malkin D, Monnat RJ, Novelli F, Pass HI, Petrini JH, Schmidt LS, Yang H. Tumour predisposition and cancer syndromes as models to study gene-environment interactions. Nat Rev Cancer. 2020 09; 20(9):533-549.
    View in: PubMed
    Score: 0.036
  12. Carbone M, Green JB, Bucci EM, Lednicky JA. Coronaviruses: Facts, Myths, and Hypotheses. J Thorac Oncol. 2020 05; 15(5):675-678.
    View in: PubMed
    Score: 0.036
  13. Carbone M, Melino G. Stearoyl CoA Desaturase Regulates Ferroptosis in Ovarian Cancer Offering New Therapeutic Perspectives. Cancer Res. 2019 Oct 15; 79(20):5149-5150.
    View in: PubMed
    Score: 0.035
  14. Carbone M, Melino G. Lipid metabolism offers anticancer treatment by regulating ferroptosis. Cell Death Differ. 2019 12; 26(12):2516-2519.
    View in: PubMed
    Score: 0.035
  15. Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019 09; 69(5):402-429.
    View in: PubMed
    Score: 0.034
  16. Carbone M, Yang H, Gaudino G. Does Chromothripsis Make Mesothelioma an Immunogenic Cancer? J Thorac Oncol. 2019 02; 14(2):157-159.
    View in: PubMed
    Score: 0.033
  17. Affar EB, Carbone M. BAP1 regulates different mechanisms of cell death. Cell Death Dis. 2018 11 19; 9(12):1151.
    View in: PubMed
    Score: 0.033
  18. Carbone M, Amelio I, Affar EB, Brugarolas J, Cannon-Albright LA, Cantley LC, Cavenee WK, Chen Z, Croce CM, Andrea A, Gandara D, Giorgi C, Jia W, Lan Q, Mak TW, Manley JL, Mikoshiba K, Onuchic JN, Pass HI, Pinton P, Prives C, Rothman N, Sebti SM, Turkson J, Wu X, Yang H, Yu H, Melino G. Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. Cell Death Differ. 2018 11; 25(11):1885-1904.
    View in: PubMed
    Score: 0.033
  19. Carbone M, Guo Z, Mao W. Improving the Accuracy of?Mesothelioma Diagnosis in China. J Thorac Oncol. 2017 08; 12(8):e132.
    View in: PubMed
    Score: 0.030
  20. Bononi A, Yang H, Giorgi C, Patergnani S, Pellegrini L, Su M, Xie G, Signorato V, Pastorino S, Morris P, Sakamoto G, Kuchay S, Gaudino G, Pass HI, Napolitano A, Pinton P, Jia W, Carbone M. Germline BAP1 mutations induce a Warburg effect. Cell Death Differ. 2017 10; 24(10):1694-1704.
    View in: PubMed
    Score: 0.030
  21. Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, Nasu M, Napolitano A, Gaudino G, Morris P, Sakamoto G, Ferris LK, Danese A, Raimondi A, Tacchetti C, Kuchay S, Pass HI, Affar EB, Yang H, Pinton P, Carbone M. BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature. 2017 06 22; 546(7659):549-553.
    View in: PubMed
    Score: 0.030
  22. Mao W, Zhang X, Guo Z, Gao Z, Pass HI, Yang H, Carbone M. Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China. JAMA Oncol. 2017 04 01; 3(4):562-564.
    View in: PubMed
    Score: 0.029
  23. Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T, Hasegawa S, Nakano T, Nasu M, Pastorino S, Szymiczek A, Bononi A, Tanji M, Pagano I, Gaudino G, Napolitano A, Goparaju C, Pass HI, Yang H, Carbone M. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc Natl Acad Sci U S A. 2016 11 22; 113(47):13432-13437.
    View in: PubMed
    Score: 0.028
  24. Carbone M, Shimizu D, Napolitano A, Tanji M, Pass HI, Yang H, Pastorino S. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma. Oncotarget. 2016 Sep 13; 7(37):59314-59321.
    View in: PubMed
    Score: 0.028
  25. Napolitano A, Carbone M. Malignant Mesothelioma: Time to Translate? Trends Cancer. 2016 09; 2(9):467-474.
    View in: PubMed
    Score: 0.028
  26. Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016 08; 11(8):1246-1262.
    View in: PubMed
    Score: 0.028
  27. Zhang L, Shimizu D, Killeen JL, Honda SA, Lu D, Stanoyevitch A, Lin F, Wang B, Monuki ES, Carbone M. Serous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor. Hum Pathol. 2016 07; 53:159-67.
    View in: PubMed
    Score: 0.027
  28. Baumann F, Carbone M. Environmental risk of mesothelioma in the United States: An emerging concern-epidemiological issues. J Toxicol Environ Health B Crit Rev. 2016; 19(5-6):231-249.
    View in: PubMed
    Score: 0.027
  29. Carbone M, Flores EG, Emi M, Johnson TA, Tsunoda T, Behner D, Hoffman H, Hesdorffer M, Nasu M, Napolitano A, Powers A, Minaai M, Baumann F, Bryant-Greenwood P, Lauk O, Kirschner MB, Weder W, Opitz I, Pass HI, Gaudino G, Pastorino S, Yang H. Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s. PLoS Genet. 2015 Dec; 11(12):e1005633.
    View in: PubMed
    Score: 0.027
  30. Napolitano A, Carbone M. Concerns About Presence of a Wild-Type BAP1 Allele in Absence of Nuclear Protein Expression. JAMA Dermatol. 2015 Nov; 151(11):1265-6.
    View in: PubMed
    Score: 0.026
  31. Bononi A, Napolitano A, Pass HI, Yang H, Carbone M. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med. 2015 Oct; 9(5):633-54.
    View in: PubMed
    Score: 0.026
  32. Baumann F, Buck BJ, Metcalf RV, McLaurin BT, Merkler D, Carbone M. Reply to "No Increased Risk for Mesothelioma in Relation to Natural-Occurring Asbestos in Southern Nevada". J Thorac Oncol. 2015 Jul; 10(7):e64-5.
    View in: PubMed
    Score: 0.026
  33. Baumann F, Buck BJ, Metcalf RV, McLaurin BT, Merkler DJ, Carbone M. The Presence of Asbestos in the Natural Environment is Likely Related to Mesothelioma in Young Individuals and Women from Southern Nevada. J Thorac Oncol. 2015 May; 10(5):731-737.
    View in: PubMed
    Score: 0.026
  34. Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, Baumann F, Zhang YA, Gazdar A, Kanodia S, Tiirikainen M, Flores E, Gaudino G, Becich MJ, Pass HI, Yang H, Carbone M. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015 Apr; 10(4):565-76.
    View in: PubMed
    Score: 0.025
  35. Carbone M, Gaudino G, Yang H. Recent insights emerging from malignant mesothelioma genome sequencing. J Thorac Oncol. 2015 Mar; 10(3):409-11.
    View in: PubMed
    Score: 0.025
  36. Comertpay S, Pastorino S, Tanji M, Mezzapelle R, Strianese O, Napolitano A, Baumann F, Weigel T, Friedberg J, Sugarbaker P, Krausz T, Wang E, Powers A, Gaudino G, Kanodia S, Pass HI, Parsons BL, Yang H, Carbone M. Evaluation of clonal origin of malignant mesothelioma. J Transl Med. 2014 Dec 04; 12:301.
    View in: PubMed
    Score: 0.025
  37. Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, Yang H, Carbone M. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015 Jan; 36(1):76-81.
    View in: PubMed
    Score: 0.025
  38. Qi F, Okimoto G, Jube S, Napolitano A, Pass HI, Laczko R, Demay RM, Khan G, Tiirikainen M, Rinaudo C, Croce A, Yang H, Gaudino G, Carbone M. Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-a signaling. Am J Pathol. 2013 Nov; 183(5):1654-66.
    View in: PubMed
    Score: 0.023
  39. Baumann F, Ambrosi JP, Carbone M. Asbestos is not just asbestos: an unrecognised health hazard. Lancet Oncol. 2013 Jun; 14(7):576-8.
    View in: PubMed
    Score: 0.022
  40. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013 03; 13(3):153-9.
    View in: PubMed
    Score: 0.022
  41. Bertino P, Panigada M, Soprana E, Bianchi V, Bertilaccio S, Sanvito F, Rose AH, Yang H, Gaudino G, Hoffmann PR, Siccardi A, Carbone M. Fowlpox-based survivin vaccination for malignant mesothelioma therapy. Int J Cancer. 2013 Aug 01; 133(3):612-23.
    View in: PubMed
    Score: 0.022
  42. Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, Flores EG, Gaudino G, Powers A, Bryant-Greenwood P, Krausz T, Hyjek E, Tate R, Friedberg J, Weigel T, Pass HI, Yang H. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012 Aug 30; 10:179.
    View in: PubMed
    Score: 0.021
  43. Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res. 2012 Oct 01; 18(19):5352-63.
    View in: PubMed
    Score: 0.021
  44. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, Gazdar AF, Pass HI, Yang H. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012 Jan; 227(1):44-58.
    View in: PubMed
    Score: 0.020
  45. Carbone M, Yang H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res. 2012 Feb 01; 18(3):598-604.
    View in: PubMed
    Score: 0.020
  46. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011 Aug 28; 43(10):1022-5.
    View in: PubMed
    Score: 0.020
  47. Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU, Gaudino G, Jube S, Kanodia S, Partridge CR, Pass HI, Rivera ZS, Steele I, Tuncer M, Way S, Yang H, Miller A. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A. 2011 Aug 16; 108(33):13618-23.
    View in: PubMed
    Score: 0.020
  48. Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, Franzoso G, Lotze MT, Krausz T, Pass HI, Bianchi ME, Carbone M. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A. 2010 Jul 13; 107(28):12611-6.
    View in: PubMed
    Score: 0.018
  49. Carbone M. Feasibility of immunotherapy for lymphangioleiomyomatosis. Am J Pathol. 2009 Dec; 175(6):2252-4.
    View in: PubMed
    Score: 0.017
  50. Yang H, Nasu M, Strianese O, Rivera Z, Luecke L, Carbone M. The legacy of "miracle mineral": asbestos and cancer. Hawaii Med J. 2009 Jan-Feb; 68(1):18-20.
    View in: PubMed
    Score: 0.016
  51. Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009; 21(2):97-104.
    View in: PubMed
    Score: 0.016
  52. Carbone M, Pannuti A, Zhang L, Testa JR, Bocchetta M. A novel mechanism of late gene silencing drives SV40 transformation of human mesothelial cells. Cancer Res. 2008 Nov 15; 68(22):9488-96.
    View in: PubMed
    Score: 0.016
  53. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008 Jun; 9(2-3):147-57.
    View in: PubMed
    Score: 0.016
  54. Rivera Z, Strianese O, Bertino P, Yang H, Pass H, Carbone M. The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med. 2008 Jul; 14(4):316-21.
    View in: PubMed
    Score: 0.016
  55. Bocchetta M, Eliasz S, De Marco MA, Rudzinski J, Zhang L, Carbone M. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res. 2008 Feb 15; 68(4):1022-9.
    View in: PubMed
    Score: 0.016
  56. Bocchetta M, Carbone M. SV40 Tag/p53 complexes actively promote malignant cell growth of human mesothelial cells. Cell Oncol. 2008; 30(5):455.
    View in: PubMed
    Score: 0.015
  57. Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, Pass HI, Baris YI. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer. 2007 02; 7(2):147-54.
    View in: PubMed
    Score: 0.014
  58. Carbone M, Strianese O, Theos K, Yang H. Mesothelioma. Hawaii Med J. 2007 Feb; 66(2):48-50.
    View in: PubMed
    Score: 0.014
  59. Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad AG, Vacek P, Ramos-Nino M, Mossman BT, Pass HI, Carbone M. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci U S A. 2006 Sep 19; 103(38):14128-33.
    View in: PubMed
    Score: 0.014
  60. Kroczynska B, Carbone M. Cross reactivity between many anti-human antibodies for their hamster homologs provide the tools to study the signal transduction pathway activated by asbestos and SV40 in the malignant mesothelioma model. Mol Carcinog. 2006 Jul; 45(7):537-42.
    View in: PubMed
    Score: 0.014
  61. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, Bubici C, Mossman BT, Pass HI, Testa JR, Franzoso G, Carbone M. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A. 2006 Jul 05; 103(27):10397-10402.
    View in: PubMed
    Score: 0.014
  62. Dogan AU, Baris YI, Dogan M, Emri S, Steele I, Elmishad AG, Carbone M. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res. 2006 May 15; 66(10):5063-8.
    View in: PubMed
    Score: 0.014
  63. Rdzanek M, Fresco R, Pass HI, Carbone M. Spindle cell tumors of the pleura: differential diagnosis. Semin Diagn Pathol. 2006 Feb; 23(1):44-55.
    View in: PubMed
    Score: 0.013
  64. Carbone M, Bedrossian CW. The pathogenesis of mesothelioma. Semin Diagn Pathol. 2006 Feb; 23(1):56-60.
    View in: PubMed
    Score: 0.013
  65. Carbone M, Pass HI. Evolving aspects of mesothelioma carcinogenesis: SV40 and genetic predisposition. J Thorac Oncol. 2006 Feb; 1(2):169-71.
    View in: PubMed
    Score: 0.013
  66. Carbone M, Rdzanek MA, Rudzinski JJ, De Marco MA, Bocchetta M, Ramos Ni?o M, Mossman B, Pass HI. SV40 detection in human tumor specimens. Cancer Res. 2005 Nov 01; 65(21):10120-1.
    View in: PubMed
    Score: 0.013
  67. Tanvetyanon T, Elmishad AG, Carbone M. Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link? Anticancer Res. 2005 Jan-Feb; 25(1B):429-33.
    View in: PubMed
    Score: 0.013
  68. Carbone M, Pass HI. Multistep and multifactorial carcinogenesis: when does a contributing factor become a carcinogen? Semin Cancer Biol. 2004 Dec; 14(6):399-405.
    View in: PubMed
    Score: 0.012
  69. Pass HI, Bocchetta M, Carbone M. Evidence of an important role for SV40 in mesothelioma. Thorac Surg Clin. 2004 Nov; 14(4):489-95.
    View in: PubMed
    Score: 0.012
  70. Hurtuk MG, Carbone M. A cytokeratin- and calretinin-negative staining sarcomatoid malignant mesothelioma. Anticancer Res. 2004 Sep-Oct; 24(5B):3097-102.
    View in: PubMed
    Score: 0.012
  71. Bocchetta M, Carbone M. Epidemiology and molecular pathology at crossroads to establish causation: molecular mechanisms of malignant transformation. Oncogene. 2004 Aug 23; 23(38):6484-91.
    View in: PubMed
    Score: 0.012
  72. Carbone M, Klein G, Gruber J, Wong M. Modern criteria to establish human cancer etiology. Cancer Res. 2004 Aug 01; 64(15):5518-24.
    View in: PubMed
    Score: 0.012
  73. Pass HI, Vogelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer. 2004 May-Jun; 28(3):93-174.
    View in: PubMed
    Score: 0.012
  74. Carbone M, Rdzanek MA. Pathogenesis of malignant mesothelioma. Clin Lung Cancer. 2004 Apr; 5 Suppl 2:S46-50.
    View in: PubMed
    Score: 0.012
  75. Gazdar AF, Carbone M. Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer. 2003 Nov; 5(3):177-81.
    View in: PubMed
    Score: 0.012
  76. Carbone M, Rudzinski J, Bocchetta M. High throughput testing of the SV40 Large T antigen binding to cellular p53 identifies putative drugs for the treatment of SV40-related cancers. Virology. 2003 Oct 25; 315(2):409-14.
    View in: PubMed
    Score: 0.012
  77. Carbone M, Burck C, Rdzanek M, Rudzinski J, Cutrone R, Bocchetta M. Different susceptibility of human mesothelial cells to polyomavirus infection and malignant transformation. Cancer Res. 2003 Oct 01; 63(19):6125-9.
    View in: PubMed
    Score: 0.011
  78. Carbone M, Bocchetta M, Cristaudo A, Emri S, Gazdar A, Jasani B, Lednicky J, Miele L, Mutti L, Pass HI, Ramael M, Rizzo P, Testa JR, Weggen S, Yeung A. SV40 and human brain tumors. Int J Cancer. 2003 Aug 10; 106(1):140-2; author reply 143-5.
    View in: PubMed
    Score: 0.011
  79. Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, Agostini M, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Aqeilan RI, Arama E, Baehrecke EH, Balachandran S, Bano D, Barlev NA, Bartek J, Bazan NG, Becker C, Bernassola F, Bertrand MJM, Bianchi ME, Blagosklonny MV, Blander JM, Blandino G, Blomgren K, Borner C, Bortner CD, Bove P, Boya P, Brenner C, Broz P, Brunner T, Damgaard RB, Calin GA, Campanella M, Candi E, Carbone M, Carmona-Gutierrez D, Cecconi F, Chan FK, Chen GQ, Chen Q, Chen YH, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Ciliberto G, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Daugaard M, Dawson TM, Dawson VL, De Maria R, De Strooper B, Debatin KM, Deberardinis RJ, Degterev A, Del Sal G, Deshmukh M, Di Virgilio F, Diederich M, Dixon SJ, Dynlacht BD, El-Deiry WS, Elrod JW, Engeland K, Fimia GM, Galassi C, Ganini C, Garcia-Saez AJ, Garg AD, Garrido C, Gavathiotis E, Gerlic M, Ghosh S, Green DR, Greene LA, Gronemeyer H, H?cker G, Hajn?czky G, Hardwick JM, Haupt Y, He S, Heery DM, Hengartner MO, Hetz C, Hildeman DA, Ichijo H, Inoue S, J??ttel? M, Janic A, Joseph B, Jost PJ, Kanneganti TD, Karin M, Kashkar H, Kaufmann T, Kelly GL, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Kluck R, Krysko DV, Kulms D, Kumar S, Lavandero S, Lavrik IN, Lemasters JJ, Liccardi G, Linkermann A, Lipton SA, Lockshin RA, L?pez-Ot?n C, Luedde T, MacFarlane M, Madeo F, Malorni W, Manic G, Mantovani R, Marchi S, Marine JC, Martin SJ, Martinou JC, Mastroberardino PG, Medema JP, Mehlen P, Meier P, Melino G, Melino S, Miao EA, Moll UM, Mu?oz-Pinedo C, Murphy DJ, Niklison-Chirou MV, Novelli F, N??ez G, Oberst A, Ofengeim D, Opferman JT, Oren M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pentimalli F, Pereira DM, Pervaiz S, Peter ME, Pinton P, Porta G, Prehn JHM, Puthalakath H, Rabinovich GA, Rajalingam K, Ravichandran KS, Rehm M, Ricci JE, Rizzuto R, Robinson N, Rodrigues CMP, Rotblat B, Rothlin CV, Rubinsztein DC, Rudel T, Rufini A, Ryan KM, Sarosiek KA, Sawa A, Sayan E, Schroder K, Scorrano L, Sesti F, Shao F, Shi Y, Sica GS, Silke J, Simon HU, Sistigu A, Stephanou A, Stockwell BR, Strapazzon F, Strasser A, Sun L, Sun E, Sun Q, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Troy CM, Turk B, Urbano N, Vandenabeele P, Vanden Berghe T, Vander Heiden MG, Vanderluit JL, Verkhratsky A, Villunger A, von Karstedt S, Voss AK, Vousden KH, Vucic D, Vuri D, Wagner EF, Walczak H, Wallach D, Wang R, Wang Y, Weber A, Wood W, Yamazaki T, Yang HT, Zakeri Z, Zawacka-Pankau JE, Zhang L, Zhang H, Zhivotovsky B, Zhou W, Piacentini M, Kroemer G, Galluzzi L. Apoptotic cell death in disease-Current understanding of the NCCD 2023. Cell Death Differ. 2023 05; 30(5):1097-1154.
    View in: PubMed
    Score: 0.011
  80. Bocchetta M, Miele L, Pass HI, Carbone M. Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells. Oncogene. 2003 Jan 09; 22(1):81-9.
    View in: PubMed
    Score: 0.011
  81. Carbone M, Rizzo P, Powers A, Bocchetta M, Fresco R, Krausz T. Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications. Anticancer Res. 2002 Nov-Dec; 22(6B):3443-8.
    View in: PubMed
    Score: 0.011
  82. Arienzo MM, Saftner D, Bacon SN, Robtoy E, Neveux I, Schlauch K, Carbone M, Grzymski J. Naturally occurring metals in unregulated domestic wells in Nevada, USA. Sci Total Environ. 2022 Dec 10; 851(Pt 2):158277.
    View in: PubMed
    Score: 0.011
  83. Foddis R, De Rienzo A, Broccoli D, Bocchetta M, Stekala E, Rizzo P, Tosolini A, Grobelny JV, Jhanwar SC, Pass HI, Testa JR, Carbone M. SV40 infection induces telomerase activity in human mesothelial cells. Oncogene. 2002 Feb 21; 21(9):1434-42.
    View in: PubMed
    Score: 0.010
  84. Xue J, Suarez JS, Minaai M, Li S, Gaudino G, Pass HI, Carbone M, Yang H. HMGB1 as a therapeutic target in disease. J Cell Physiol. 2021 05; 236(5):3406-3419.
    View in: PubMed
    Score: 0.009
  85. Xue J, Patergnani S, Giorgi C, Suarez J, Goto K, Bononi A, Tanji M, Novelli F, Pastorino S, Xu R, Caroccia N, Dogan AU, Pass HI, Tognon M, Pinton P, Gaudino G, Mak TW, Carbone M, Yang H. Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy. Proc Natl Acad Sci U S A. 2020 10 13; 117(41):25543-25552.
    View in: PubMed
    Score: 0.009
  86. Pass HI, Alimi M, Carbone M, Yang H, Goparaju CM. Mesothelioma Biomarkers: Discovery in Search of Validation. Thorac Surg Clin. 2020 Nov; 30(4):395-423.
    View in: PubMed
    Score: 0.009
  87. Pass HI, Alimi M, Carbone M, Yang H, Goparaju CM. Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network. Cancer Epidemiol Biomarkers Prev. 2020 12; 29(12):2524-2540.
    View in: PubMed
    Score: 0.009
  88. Lee HJ, Pham T, Chang MT, Barnes D, Cai AG, Noubade R, Totpal K, Chen X, Tran C, Hagenbeek T, Wu X, Eastham-Anderson J, Tao J, Lee W, Bastian BC, Carbone M, Webster JD, Dey A. The Tumor Suppressor BAP1 Regulates the Hippo Pathway in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2020 04 15; 80(8):1656-1668.
    View in: PubMed
    Score: 0.009
  89. Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS. Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. J Thorac Oncol. 2019 10; 14(10):1704-1717.
    View in: PubMed
    Score: 0.009
  90. Daou S, Barbour H, Ahmed O, Masclef L, Baril C, Sen Nkwe N, Tchelougou D, Uriarte M, Bonneil E, Ceccarelli D, Mashtalir N, Tanji M, Masson JY, Thibault P, Sicheri F, Yang H, Carbone M, Therrien M, Affar EB. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1. Nat Commun. 2018 10 22; 9(1):4385.
    View in: PubMed
    Score: 0.008
  91. Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667.
    View in: PubMed
    Score: 0.008
  92. Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. J Thorac Oncol. 2018 09; 13(9):1269-1283.
    View in: PubMed
    Score: 0.008
  93. McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T. Progress in the Management of Malignant Pleural?Mesothelioma in 2017. J Thorac Oncol. 2018 05; 13(5):606-623.
    View in: PubMed
    Score: 0.008
  94. Pellegrini L, Xue J, Larson D, Pastorino S, Jube S, Forest KH, Saad-Jube ZS, Napolitano A, Pagano I, Negi VS, Bianchi ME, Morris P, Pass HI, Gaudino G, Carbone M, Yang H. HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. Oncotarget. 2017 Apr 04; 8(14):22649-22661.
    View in: PubMed
    Score: 0.007
  95. Guo Z, Carbone M, Zhang X, Su D, Sun W, Lou J, Gao Z, Shao D, Chen J, Zhang G, Hu J, Chen K, Wang F, Pass HI, Yu H, Napolitano A, Yang H, Mao W. Improving the Accuracy of Mesothelioma Diagnosis in China. J Thorac Oncol. 2017 04; 12(4):714-723.
    View in: PubMed
    Score: 0.007
  96. Ransohoff KJ, Jaju PD, Jaju PD, Tang JY, Carbone M, Leachman S, Sarin KY. Familial skin cancer syndromes: Increased melanoma risk. J Am Acad Dermatol. 2016 Mar; 74(3):423-34; quiz 435-6.
    View in: PubMed
    Score: 0.007
  97. Pass HI, Goparaju C, Espin-Garcia O, Donington J, Carbone M, Patel D, Chen Z, Feld R, Cho J, Gadgeel S, Wozniak A, Chachoua A, Leighl N, Tsao MS, de Perrot M, Xu W, Liu G. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. J Thorac Oncol. 2016 06; 11(6):900-9.
    View in: PubMed
    Score: 0.007
  98. Napolitano A, Antoine DJ, Pellegrini L, Baumann F, Pagano I, Pastorino S, Goparaju CM, Prokrym K, Canino C, Pass HI, Carbone M, Yang H. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. Clin Cancer Res. 2016 06 15; 22(12):3087-96.
    View in: PubMed
    Score: 0.007
  99. Daou S, Hammond-Martel I, Mashtalir N, Barbour H, Gagnon J, Iannantuono NV, Nkwe NS, Motorina A, Pak H, Yu H, Wurtele H, Milot E, Mallette FA, Carbone M, Affar el B. The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer. J Biol Chem. 2015 Nov 27; 290(48):28643-63.
    View in: PubMed
    Score: 0.007
  100. Hoffmann PR, Panigada M, Soprana E, Terry F, Bandar IS, Napolitano A, Rose AH, Hoffmann FW, Ndhlovu LC, Belcaid M, Moise L, De Groot AS, Carbone M, Gaudino G, Matsui T, Siccardi A, Bertino P. Preclinical development of HIvax: Human survivin highly immunogenic vaccines. Hum Vaccin Immunother. 2015; 11(7):1585-95.
    View in: PubMed
    Score: 0.006
  101. Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, Seepo S, Meyerson M, Pass HI. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015 Jan 15; 75(2):264-9.
    View in: PubMed
    Score: 0.006
  102. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012 Oct 11; 367(15):1417-27.
    View in: PubMed
    Score: 0.005
  103. Ostroff RM, Mehan MR, Stewart A, Ayers D, Brody EN, Williams SA, Levin S, Black B, Harbut M, Carbone M, Goparaju C, Pass HI. Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One. 2012; 7(10):e46091.
    View in: PubMed
    Score: 0.005
  104. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, Pass HI, Gaudino G, Carbone M, Yang H. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012 Jul 01; 72(13):3290-301.
    View in: PubMed
    Score: 0.005
  105. Qi F, Carbone M, Yang H, Gaudino G. Simian virus 40 transformation, malignant mesothelioma and brain tumors. Expert Rev Respir Med. 2011 Oct; 5(5):683-97.
    View in: PubMed
    Score: 0.005
  106. Altomare DA, Menges CW, Xu J, Pei J, Zhang L, Tadevosyan A, Neumann-Domer E, Liu Z, Carbone M, Chudoba I, Klein-Szanto AJ, Testa JR. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One. 2011 Apr 19; 6(4):e18828.
    View in: PubMed
    Score: 0.005
  107. Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Butnor KJ, Pass HI, Carbone M, Testa JR, Heintz NH, Mossman BT. ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int J Cancer. 2011 Sep 01; 129(5):1075-86.
    View in: PubMed
    Score: 0.005
  108. Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Pass HI, Carbone M, Testa JR, Mossman BT. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer. 2010 Dec 15; 9:314.
    View in: PubMed
    Score: 0.005
  109. Hillegass JM, Blumen SR, Cheng K, MacPherson MB, Alexeeva V, Lathrop SA, Beuschel SL, Steinbacher JL, Butnor KJ, Ramos-Ni?o ME, Shukla A, James TA, Weiss DJ, Taatjes DJ, Pass HI, Carbone M, Landry CC, Mossman BT. Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int J Cancer. 2011 Jul 01; 129(1):233-44.
    View in: PubMed
    Score: 0.005
  110. Flores RM, Riedel E, Donington JS, Alago W, Ihekweazu U, Krug L, Rosenzweig K, Adusumilli PS, Carbone M, Pass HI. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol. 2010 Oct; 5(10):1649-54.
    View in: PubMed
    Score: 0.005
  111. Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ, Testa JR, Pass HI, Carbone M, Steele C, Mossman BT. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci. 2010 Aug; 1203:7-14.
    View in: PubMed
    Score: 0.005
  112. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT. Cancer and inflammation: promise for biologic therapy. J Immunother. 2010 May; 33(4):335-51.
    View in: PubMed
    Score: 0.005
  113. Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, Benjamin S, Aharonov R. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 2010 Mar 01; 70(5):1916-24.
    View in: PubMed
    Score: 0.004
  114. Shukla A, Bosenberg MW, MacPherson MB, Butnor KJ, Heintz NH, Pass HI, Carbone M, Testa JR, Mossman BT. Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis. Am J Pathol. 2009 Nov; 175(5):2197-206.
    View in: PubMed
    Score: 0.004
  115. Ivanov SV, Miller J, Lucito R, Tang C, Ivanova AV, Pei J, Carbone M, Cruz C, Beck A, Webb C, Nonaka D, Testa JR, Pass HI. Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer. 2009 Feb 01; 124(3):589-99.
    View in: PubMed
    Score: 0.004
  116. Bertino P, Carbone M, Pass H. Chemotherapy of malignant pleural mesothelioma. Expert Opin Pharmacother. 2009 Jan; 10(1):99-107.
    View in: PubMed
    Score: 0.004
  117. Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg. 2008 Aug; 86(2):383-9; discussion 390.
    View in: PubMed
    Score: 0.004
  118. Beck AK, Pass HI, Carbone M, Yang H. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies. Future Oncol. 2008 Jun; 4(3):341-9.
    View in: PubMed
    Score: 0.004
  119. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008 Mar; 135(3):620-6, 626.e1-3.
    View in: PubMed
    Score: 0.004
  120. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 2008 Jan; 85(1):265-72; discussion 272.
    View in: PubMed
    Score: 0.004
  121. Ramos-Nino ME, Blumen SR, Sabo-Attwood T, Pass H, Carbone M, Testa JR, Altomare DA, Mossman BT. HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Am J Respir Cell Mol Biol. 2008 Feb; 38(2):209-17.
    View in: PubMed
    Score: 0.004
  122. Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, Mossman BT. Cellular and molecular parameters of mesothelioma. J Cell Biochem. 2006 Jul 01; 98(4):723-34.
    View in: PubMed
    Score: 0.003
  123. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005 Oct 13; 353(15):1564-73.
    View in: PubMed
    Score: 0.003
  124. Suzuki M, Toyooka S, Shivapurkar N, Shigematsu H, Miyajima K, Takahashi T, Stastny V, Zern AL, Fujisawa T, Pass HI, Carbone M, Gazdar AF. Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogene. 2005 Feb 10; 24(7):1302-8.
    View in: PubMed
    Score: 0.003
  125. Wali A, Morin PJ, Hough CD, Lonardo F, Seya T, Carbone M, Pass HI. Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer. 2005 Apr; 48(1):19-29.
    View in: PubMed
    Score: 0.003
  126. Pass HI, Liu Z, Wali A, Bueno R, Land S, Lott D, Siddiq F, Lonardo F, Carbone M, Draghici S. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res. 2004 Feb 01; 10(3):849-59.
    View in: PubMed
    Score: 0.003
  127. Toyooka S, Carbone M, Toyooka KO, Bocchetta M, Shivapurkar N, Minna JD, Gazdar AF. Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. Oncogene. 2002 Jun 20; 21(27):4340-4.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support